Macrophage-modulating cytokines predict adverse outcome in heart failure

Thrombosis and Haemostasis

Volumn 103, Issue 2, 2010, Pages 435-441

  Hohensinner, Philipp J ^a,b   Rychli, Kathrin ^a   Zorn, Gerlinde ^a   Hülsmann, Martin ^a   Berger, Rudolf ^a   Mörtl, Deddo ^a   Richter, Bernhard ^a   Huber, Kurt ^b,c   Wojta, Johann ^a,b   Pacher, Richard ^a   Niessner, Alexander ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Ludwig Boltzmann Cluster for Cardiovascular Research   (Austria)

^c WILHELMINEN HOSPITAL   (Austria)

Author keywords

Cardiomyopathy; Cytokines; Heart failure; Macrophages

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; COLONY STIMULATING FACTOR 1; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MONOCYTE CHEMOTACTIC PROTEIN 1; RENIN INHIBITOR;

ADULT; AGED; ARTICLE; CARDIOMYOPATHY; CONCENTRATION RESPONSE; CYTOKINE RELEASE; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HAZARD RATIO; HEART FAILURE; HOSPITAL READMISSION; HUMAN; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATHOPHYSIOLOGY; PLASMA; PRIORITY JOURNAL; RISK FACTOR;

AGED; AGED, 80 AND OVER; CARDIOMYOPATHIES; CHEMOKINE CCL2; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GRANULOCYTE COLONY-STIMULATING FACTOR; HEART FAILURE; HOSPITALIZATION; HUMANS; MACROPHAGE COLONY-STIMULATING FACTOR; MACROPHAGES; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 75749098119     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-06-0399     Document Type: Article

References (34)

1. Yndestad A, Damas JK, Oie E, et al. Systemic inflammation in heart failure - the whys and wherefores. Heart Fail Rev 2006; 11: 83-92.
2. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006; 354: 610-621.
3. Damas JK, Gullestad L, Ueland T, et al. CXC-chemokines, a new group of cytokines in congestive heart failure - possible role of platelets and monocytes. Cardiovasc Res 2000; 45: 428-436.
4. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 2002; 53: 31-47.
5. Devaux B, Scholz D, Hirche A, et al. Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure. Eur Heart J 1997; 18: 470-479.
6. Hanriot D, Bello G, Ropars A, et al. C-reactive protein induces pro- and anti-inflammatory effects, including activation of the liver X receptor alpha, on human monocytes. Thromb Haemost 2008; 99: 558-569.
7. Aukrust P, Yndestad A, Smith C, et al. Chemokines in cardiovascular risk prediction. Thromb Haemost 2007; 97: 748-754.
8. Aukrust P, Ueland T, Muller F, et al. Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation 1998; 97: 1136-1143.
9. Behr TM, Wang X, Aiyar N, et al. Monocyte chemoattractant protein-1 is upregulated in rats with volume-overload congestive heart failure. Circulation 2000; 102: 1315-1322.
10. Okada M, Matsumori A, Ono K, et al. Cyclic stretch upregulates production of interleukin-8 and monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 in human endothelial cells. Arterioscler Thromb Vasc Biol 1998; 18: 894-901.
11. Goser S, Ottl R, Brodner A, et al. Critical role for monocyte chemoattractant protein-1 and macrophage inflammatory protein-1alpha in induction of experimental autoimmune myocarditis and effective anti-monocyte chemoattractant protein-1 gene therapy. Circulation 2005; 112: 3400-3407.
12. de Lemos JA, Morrow DA, Blazing MA, et al. Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial. J Am Coll Cardiol 2007; 50: 2117-2124.
13. Pixley FJ, Stanley ER. CSF-1 regulation of the wandering macrophage: complexity in action. Trends Cell Biol 2004; 14: 628-638.
14. Hohensinner PJ, Kaun C, Rychli K, et al. Monocyte chemoattractant protein (MCP-1) is expressed in human cardiac cells and is differentially regulated by inflammatory mediators and hypoxia. FEBS Lett 2006; 580: 3532-3538.
15. Dewald O, Ren G, Duerr GD, et al. Of mice and dogs: species-specific differences in the inflammatory response following myocardial infarction. Am J Pathol 2004; 164: 665-677.
16. Yano T, Miura T, Whittaker P, et al. Macrophage colony-stimulating factor treatment after myocardial infarction attenuates left ventricular dysfunction by accelerating infarct repair. J Am Coll Cardiol 2006; 47: 626-634.
17. Okazaki T, Ebihara S, Asada M, et al. Macrophage colony-stimulating factor improves cardiac function after ischemic injury by inducing vascular endothelial growth factor production and survival of cardiomyocytes. Am J Pathol 2007; 171: 1093-1103.
18. Chitu V, Stanley ER. Colony-stimulating factor-1 in immunity and inflammation. Curr Opin Immunol 2006; 18: 39-48.
19. Lapidot T, Petit I. Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol 2002; 30: 973-981.
20. Kastrup J, Ripa RS, Wang Y, et al. Myocardial regeneration induced by granulocyte-colony-stimulating factor mobilization of stem cells in patients with acute or chronic ischaemic heart disease: a non-invasive alternative for clinical stem cell therapy? Eur Heart J 2006; 27: 2748-2754.
21. Harada M, Qin Y, Takano H, et al. G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes. Nat Med 2005; 11: 305-311.
22. Date T, Mochizuki S, Belanger AJ, et al. Differential effects of membrane and soluble Fas ligand on cardiomyocytes: role in ischemia/reperfusion injury. J Mol Cell Cardiol 2003; 35: 811-821.
23. Kuethe F, Figulla HR, Herzau M, et al. Treatment with granulocyte colony-stimulating factor for mobilization of bone marrow cells in patients with acute myocardial infarction. Am Heart J 2005; 150: 115.
24. Ripa RS, Jorgensen E, Wang Y, et al. Stem cell mobilization induced by subcutaneous granulocyte-colony stimulating factor to improve cardiac regeneration after acute ST-elevation myocardial infarction: result of the double-blind, randomized, placebo-controlled stem cells in myocardial infarction (STEMMI) trial. Circulation 2006; 113: 1983-1992.
25. Zohlnhofer D, Ott I, Mehilli J, et al. Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial. J Am Med Assoc 2006; 295: 1003-1010.
26. Engelmann MG, Theiss HD, Hennig-Theiss C, et al. Autologous bone marrow stem cell mobilization induced by granulocyte colony-stimulating factor after subacute ST-segment elevation myocardial infarction undergoing late revascularization: final results from the G-CSF-STEMI (Granulocyte Colony-Stimulating Factor ST-Segment Elevation Myocardial Infarction) trial. J Am Coll Cardiol 2006; 48: 1712-1721.
27. Niessner A, Hohensinner PJ, Rychli K, et al. Prognostic value of apoptosis markers in advanced heart failure patients. Eur Heart J 2009; 30: 789-796.
28. Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease. Circ Res 2004; 95: 858-866.
29. Lehmann MH, Kuhnert H, Muller S, et al. Monocyte chemoattractant protein 1 (MCP-1) gene expression in dilated cardiomyopathy. Cytokine 1998; 10: 739-746.
30. Tham DM, Martin-McNulty B, Wang YX, et al. Angiotensin II is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs. Physiol Genomics 2002; 11: 21-30.
31. da Cunha V, Tham DM, Martin-McNulty B, et al. Enalapril attenuates angiotensin II-induced atherosclerosis and vascular inflammation. Atherosclerosis 2005; 178: 9-17.
32. De Ciuceis C, Amiri F, Brassard P, et al. Reduced vascular remodeling, endothelial dysfunction, and oxidative stress in resistance arteries of angiotensin II-infused macrophage colony-stimulating factor-deficient mice: evidence for a role in inflammation in angiotensin-induced vascular injury. Arterioscler Thromb Vasc Biol 2005; 25: 2106-2113.
33. Sivasubramanian N, Coker ML, Kurrelmeyer KM, et al. Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. Circulation 2001; 104: 826-831.
34. Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004; 109: 1594-1602.